Bioqual IncOTC Pink - Current Information:BIOQ
- LAST PRICE75.0000
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0000 / 75.0000
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
Apr 22, 2024
BIOQUAL Presents Unaudited Financial Results for Third Quarter of Fiscal Year 2024, from 12:02PM ET on Monday Apr 22, 2024 by Dow Jones
12:02PM ET on Monday Apr 22, 2024 by Dow JonesPress Release: BIOQUAL Presents Unaudited Financial Results for Third Quarter of Fiscal Year 2024, from 12:02PM ET on Monday Apr 22, 2024 by Dow Jones
12:02PM ET on Monday Apr 22, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Bioqual Inc | 67.1M | -146.6x | -25.28% |
Cidara Therapeutics Inc | 59.3M | -50.0x | --- |
Protalix Biotherapeutics Inc | 86.2M | 16.6x | --- |
MDxHealth SA | 67.4M | 0.0x | --- |
Champions Oncology Inc | 68.8M | -7.0x | --- |
Sorrento Therapeutics Inc | 11.0M | 0.0x | --- |
Company Information
Bioqual, Inc. is engaged in performing contract research services, which is focused on in vivo models of human diseases, including COVID-19, acquired immune deficiency syndrome (AIDS), influenza, Mpox, respiratory syncytial virus (RSV) infection, Flavivirus infections, including zika and dengue, malaria, hepatitis, and cancer. It is involved in the evaluation of vaccines, vaccine therapeutics, microbicides, and drug therapies. The Company also performs in vitro contract research services. The in vitro services include sample processing, virus stock generation, quantitation of infectious virus, virus neutralization assays, hemagglutination inhibition assay, quantitative PCR, antigen and antibody ELISA detection assays, flow cytometry, lymphocyte proliferation and other cell-based assays. It also provides research services in herpes simplex in rodents, filariasis in rhesus macaques, chikungunya in rodents and macaques and dengue in rodents and macaques.
Contact Information
- Headquarters
- 9600 Medical Center Drive, Suite 101ROCKVILLE, MD, United States 20850-3336
- Phone
- 240-404-7654
- Fax
- 240-404-7664
Executives
- Chairman of the Board, President, Chief Executive Officer
- Mark Lewis
- Chief Financial Officer
- Charles Kirk
- Chief Scientific Officer
- Hanne Elyard
- Vice President - Operations
- MITCH FRANKLIN
- Vice President - Facility Operations, Director - Information Technology
- Chander Sarma
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $67.1M |
|---|---|
Revenue (TTM) | $61.6M |
Shares Outstanding | 894.4K |
Dividend Yield | 0.67% |
Annual Dividend Rate | 0.5000 USD |
Ex-Dividend Date | 10-05-23 |
Pay Date | 10-27-23 |
Beta | -0.30 |
EPS | $-0.51 |
Book Value | $42.05 |
P/E Ratio | -146.6x |
Price/Sales (TTM) | 1.1 |
Price/Cash Flow (TTM) | 32.4x |
Operating Margin | -1.54% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
